Skip to main content

Table 1 Study characteristics

From: Canadian oncogenic human papillomavirus cervical infection prevalence: Systematic review and meta-analysis

Reference Study population; year of data collection; province(s) Sample size Mean age (SD) or age range Method of detection #
cases‡
HPV types detected Overall HPV prevalence
(any type)†
HR HPV prevalence Methodological quality components
Peng
1988 [30]
Patients with abnormal pap smears
Dates NR
Ontario
200 NR In-situ hybridization 28 (HR16, 18) Specific HPV types probed§ NA 14%
(HR16, 18)
1.N, 2.Y, 3.U, 4.N, 5.Y, 6.N, 7.Y
Caussy
1990 [42]
Cases with cervical cancer, controls with CIN without cervical cancer
1960-1986
British Columbia
141 35.6 (24) In-situ hybridization 31 HR-16, 18 22% 17.0% 1.N, 2.Y, 3.U, 4.Y, 5.N, 6.N, 7.Y
Duggan
1990 [29]
Patients referred to colposcopy clinic
Dates NR
Alberta
119 NR Dot blot hybridization 28 (HPV 16/18/33) HR-16, 18, 33
LR-6, 11
NA 23.5%
(HPV 16/18/33)
1.N, 2.Y, 3.U, 4.N, 5.Y, 6.N, 7.U
Rohan
1991 [60]
University Students: Routine Screening
1990
Ontario
105 23 (median age) PCR (E7/E6) 19 HR-16, 18, 33
LR-6, 11
12.3% 10.5% 1.Y, 2.Y, 3.Y, 4.N, 5.Y, 6.Y, 7.Y
Guijon
1993 [47]
Patients referred to colposcopy clinic
1985-1990
Manitoba
409 25.7 (NR) In-situ hybridization 280 HR-16, 18, 33
LR-6, 11
NA 68.5%
(HPV 16/18)
1.N, 2.Y, 3.Y, 4.N, 5.Y, 6.N, 7.Y
Brisson
1994 [41]
Patients referred to colposcopy clinic
1988-1989
Quebec
1140   Southern Blot 28.2 (6.6) HR-16, 18
LR-6, 11
NA 24.3% (HPV-16) 1.N, 2.Y, 3.Y, 4.N, 5.Y, 6.N, 7.Y
Bosch
1995 [38]
Tumor biopsies of invasive cervical cancer
1989-1992
Province NR
46 NR PCR (MY09/
MY11)
43 HR-16 93.5% 91.3% 1.NA, 2.Y, 3.NA, 4.N, 5.N, 6.Y, 7.Y
Duggan 1995 [43]*
[27, 68]
Cervical cancer tumour biopsies
1970-1990
Alberta
76 47.3 (16.7) Dot blot supplemented by PCR 53 All 70.0% 65.8% 1.NA, 2.Y, 3.NA 4.Y, 5.N, 6.Y, 7.Y
Franco
1996 [46]
Cervical cancer tumour biopsies
1983-1990
Quebec
69 NR PCR (GP5+/GP6+) 59 HR-16, 18, 31, 33, 35
LR-6, 11
85.5% 40.6%
(HPV 16/18)
1.NA, 2.Y, 3.NA, 4.N, 5.N, 6.Y, 7.Y
Young
1997 [62]
General Public (Low-income, inner-city area): Routine Screening
1992-1995
Manitoba
1263 73% less than 30 years PCR (MY09/
MY11)
411 HR-16, 18, 31
LR-6, 11
32.5% 18.0%
(HPV 16/18)
1.N, 2.Y, 3.U, 4.N, 5.Y, 6.Y, 7.Y
Duggan 1997 [44]*
[67, 69, 70]
Cervical biopsies
NR
Alberta
525 28.0 PCR 249 HR-16, 18, 31, 33, 35
LR-6, 11
47.4% 28.0%
(HPV 16/18)
1.N, 2.Y, 3.U, 4.Y, 5.Y, 6.Y, 7. U
Michael
1999 [55]
University Students: Routine Screening
NR
Ontario
99 NR PCR (MY09/
MY11)
40 HR-16, 18, 31, 33, 35
LR-6, 11
40.4% 10.1%
(HPV 16/18)
1.N, 2.Y, 3.Y, 4.Y, 5.Y, 6.Y, 7.Y
Hankins 1999 [49]* [63, 64, 66, 71] HIV positive
1993-2000
Multiple provinces
375 32.5 PCR (MY09/
MY11)
252 HR-16, 18 67.2% 49.1% 1.N, 2.Y, 3.U, 4.Y, 5.Y, 6.Y, 7.Y
Richardson 2000 [58] University Students: Routine Screening
1992-1993
Quebec
375 18-24 PCR (MY09/
MY11)
85 HR- [11]
LR-6,11,53
22.7% 11.8% 1.N, 2.Y, 3.Y, 4.N, 5.Y, 6.Y, 7.U
Sellors 2000a [31]*
[65, 74, 79]
General Public: Routine Screening
1998-1999
Ontario
955 (HC-II);
824 (PCR)
15-49 PCR (MY09/
MY11;
HC-II
110 HR- [11]
LR- [16]
13.3% 12.7%
(HC-II)
1.Y, 2.Y, 3.Y, 4.Y, 5.Y, 6.Y, 7.Y
Sellors 2000b [35] Patients recalled after an Abnormal Pap on Routine Screening
1996-1997
Ontario
200 31.5 (9.4) HC-II/PCR (L1) 125 HR- [13]
LR-6,11,42,53
62.5% 90.3% HSIL 1.N, 2.Y, 3.Y, 4.N, 5.Y, 6.Y, 7.Y
Ratnam 2000 [57] General Public: Routine Screening
1996-1998
Newfoundland
2098 30 (NR) HC-I/HC-II 227 (HR13) HR- [13]
LR-6,11,42,53
NA 10.8% 1.Y, 2.Y, 3.Y, 4.Y, 5.Y, 6.Y, 7.Y
Feoli-Fonseca 2001 [45]*
[77]
Biopsies suspected of HPV
Dates NR
Quebec
691 26.1 PCR (MY09/
MY11/GP5+/GP6+)
484 HR- [13] 70.0% 92.0% (CIN III)
100% (carcinoma in situ)
1.NA, 2.Y, 3.NA, 4.Y, 5.N, 6.Y, 7.Y
Healey
2001 [50]*
[72, 73]
General Public (Inuit): Routine Screening
1999
Nunavut
1290 13-79 HC-II 333 HR- [13]   25.8% 1.Y, 2.Y, 3.Y, 4.Y, 5.Y, 6.Y, 7.Y
Tran-Thanh
2002 [61]*
[80]
Cases with SIL or invasive cancer and controls with normal cytology and no history of cervical disease
1998-2000
Quebec
320 16-73 PCR (MY09/
MY11)
206 HR- [13] 64.4%   1.N, 2.Y, 3.Y, 4.N, 5.Y, 6.Y, 7.Y
Sellors 2002 [32] General Public: Routine Screening
1999-2000
Ontario
156 50 and over HCII/PCR 13 HR- [13]
LR- [14]
NA 8.3%
(HC-II)
1.N, 2.Y, 3.N, 4.N, 5.Y, 6.Y, 7.U
Richardson
2003 [59]*
[81]
University Students: Routine Screening
1996-1998
Quebec
621 83% under age 27 years; mean age 23 (NR) PCR (MY09/
MY11)
180 HR- [13] 29% 21.8% 1.N, 2.Y, 3.U, 4.N, 5.Y, 6.Y, 7.Y
Lytwyn
2003 [75]*
[53]
Patients recalled after an Abnormal Pap: ASCUS or LSIL only
1995-1998
Ontario
105 30.3 (8.1) HC-II 57 (HR13) HR- [13]
LR- [14]
NA 54.3% 1.Y, 2.Y, 3.Y, 4.Y, 5.Y, 6.Y, 7.Y
Koushik
2005 [52]*
[76, 78]
General Public: Cases with CIN from colposcopy clinics, controls with normal pap from screening.
2001-2003
Quebec
357 cases,
760 controls
32.0 (9.1) Cases,
31.7 (10.0) Controls
PCR (MY09/
MY11)
579 HR- [13] 51.8% 41.8% 1.N, 2.Y, 3.Y, 4.Y, 5.Y, 6.Y, 7.Y
Mayrand
2006 [54]
General Public: Routine Screening
2002-2004
Quebec, Newfoundland
9620 NR HCII 591 HR- [13]
LR- [24]
NA 6.1% 1.N, 2.Y, 3.Y, 4.Y, 5.Y, 6.Y, 7.Y
Ogilvie
2007 [56]
Sex trade workers or women with a history of alcohol or drug abuse
2004-2005
British Columbia
151 39.0 HC-II 43 (HC13) HR- [13] NA 28.5% 1.N, 2.Y, 3.Y, 4.N, 5.Y, 6.Y, 7.Y
Kapala 2007 [51] General Public: Routine Screening
Date NR
Ontario
320 73% age 30 or greater HC-II 92 (HR13) HR- [13] NA 28.8% 1.NA, 2.Y, 3.NA, 4.N, 5.Y, 6.Y, 7.U
Antionishyn 2008 [40] Cervical biopsies
1995-1998
Saskatchewan
1355 NR PCR (GP5+/GP6+) 753 HR- [13] 55.6% 56.8% CIN III (16 and 18) 1.NA, 2.Y, 3.NA, 4.N, 5.Y, 6.Y, 7.Y
Hamlin-Douglas 2008 [48] General Public (Inuit): Routine Screening
2002-2007
Quebec
554 35.5 (14.4) PCR (MY09/
MY11)
160 All 28.9% 20.4% 1.Y, 2.Y, 3.N, 4.Y, 5.Y, 6.Y, 7.Y
Moore
2009 [39]
Population-based estimates weighted by cytology
2004
British Columbia
4821 13-86 PCR (GP5+/GP6+) 810 All 16.8% 13.9% 1.NA, 2.Y, 3.NA, 4.Y, 5.Y, 6.Y, 7.N
  1. Notes: * major publication and other references are companion reports, number of women positive for human papillomavirus, † calculated by using the "number of cases" value as the numerator and the "sample size" as the denominator, expressed as a percent. Abbreviations: SD standard deviation, NR not reported, HC hybrid capture, PCR polymerase chain reaction.